187 related articles for article (PubMed ID: 38354090)
1. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
Rees MJ; Kumar S
Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
[TBL] [Abstract][Full Text] [Related]
2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
3. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
4. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
Martino M; Paviglianiti A
Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
[No Abstract] [Full Text] [Related]
5. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
6. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
Guo R; Lu W; Zhang Y; Cao X; Jin X; Zhao M
Front Immunol; 2022; 13():839097. PubMed ID: 35320942
[TBL] [Abstract][Full Text] [Related]
7. Targeting BCMA in Multiple Myeloma.
Tan CR; Shah UA
Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
[TBL] [Abstract][Full Text] [Related]
8. BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.
Watson E; Djebbari F; Rampotas A; Ramasamy K
Expert Rev Hematol; 2022 Jun; 15(6):503-517. PubMed ID: 35633050
[TBL] [Abstract][Full Text] [Related]
9. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
10. BCMA-targeted immunotherapy for multiple myeloma.
Yu B; Jiang T; Liu D
J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
[TBL] [Abstract][Full Text] [Related]
11. Rethinking mechanisms of neurotoxicity with BCMA directed therapy.
Mohyuddin GR; Banerjee R; Alam Z; Berger KE; Chakraborty R
Crit Rev Oncol Hematol; 2021 Oct; 166():103453. PubMed ID: 34461271
[TBL] [Abstract][Full Text] [Related]
12. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.
Abramson HN
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707894
[TBL] [Abstract][Full Text] [Related]
13. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
14. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
15. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy.
Quazi S
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e392-e404. PubMed ID: 34992008
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
[TBL] [Abstract][Full Text] [Related]
17. [Future therapeutic strategies for multiple myeloma].
Ishida T
Rinsho Ketsueki; 2022; 63(6):635-645. PubMed ID: 35831199
[TBL] [Abstract][Full Text] [Related]
18. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
19. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
20. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
